Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Recommendation of “Buy” from Brokerages

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) has received an average rating of “Buy” from the four analysts that are covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $7.31.

AMRX has been the topic of several research analyst reports. Piper Sandler raised their target price on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. The Goldman Sachs Group raised their target price on shares of Amneal Pharmaceuticals from $5.50 to $6.25 and gave the stock a “buy” rating in a report on Monday, March 4th. StockNews.com downgraded shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 4th. Finally, Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Monday, January 29th.

Amneal Pharmaceuticals Trading Up 1.2 %

Shares of Amneal Pharmaceuticals stock opened at $6.12 on Thursday. Amneal Pharmaceuticals has a 12-month low of $1.74 and a 12-month high of $6.46. The company has a 50-day simple moving average of $5.73 and a 200 day simple moving average of $5.24. The company has a quick ratio of 0.94, a current ratio of 1.63 and a debt-to-equity ratio of 121.31. The stock has a market capitalization of $1.88 billion, a P/E ratio of -19.74 and a beta of 1.33.

Amneal Pharmaceuticals (NASDAQ:AMRX) last issued its earnings results on Friday, March 1st. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.07. The company had revenue of $616.98 million for the quarter, compared to analyst estimates of $630.67 million. Amneal Pharmaceuticals had a negative net margin of 3.51% and a positive return on equity of 126.04%. Research analysts expect that Amneal Pharmaceuticals will post 0.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of AMRX. Vanguard Group Inc. raised its stake in Amneal Pharmaceuticals by 3.1% during the third quarter. Vanguard Group Inc. now owns 13,548,300 shares of the company’s stock worth $57,174,000 after acquiring an additional 412,599 shares in the last quarter. Rubric Capital Management LP raised its stake in Amneal Pharmaceuticals by 98.8% during the fourth quarter. Rubric Capital Management LP now owns 8,000,000 shares of the company’s stock worth $48,560,000 after acquiring an additional 3,975,500 shares in the last quarter. LSV Asset Management raised its stake in Amneal Pharmaceuticals by 10.5% during the third quarter. LSV Asset Management now owns 1,429,300 shares of the company’s stock worth $6,032,000 after acquiring an additional 136,100 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Amneal Pharmaceuticals by 2.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,329,508 shares of the company’s stock worth $8,070,000 after acquiring an additional 26,875 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its stake in Amneal Pharmaceuticals by 3.4% during the fourth quarter. Teacher Retirement System of Texas now owns 744,752 shares of the company’s stock worth $4,521,000 after acquiring an additional 24,651 shares in the last quarter. Institutional investors and hedge funds own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.